Trial record 1 of 1 for:    Cytarabine and Lenalidomide AND Buffalo
Previous Study | Return to List | Next Study

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01246622
Recruitment Status : Active, not recruiting
First Posted : November 23, 2010
Last Update Posted : March 29, 2018
National Cancer Institute (NCI)
Celgene Corporation
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : May 1, 2014
  Estimated Study Completion Date : June 1, 2018